ArticleAmerican journal of human genetics1999
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.
Article in American journal of human genetics, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Systematic meta-analyses of gene-specific genetic association studies in prostate cancer.Oncotarget · 2016Pooled it
- Article
- Article
- Article
- Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.Journal of the National Cancer Institute · 2022Article
- Genome-wide association and functional interrogation identified a variant at 3p26.1 modulating ovarian cancer survival among Chinese women.Cell discovery · 2021Article
- Peripheral bloodJournal of gynecologic oncology · 2021Article
- Germline genomic patterns are associated with cancer risk, oncogenic pathways, and clinical outcomes.Science advances · 2020Article
- Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes.International journal of cancer · 2020Article
- Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.British journal of cancer · 2019Article
- Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.Journal of the National Cancer Institute · 2015Article
- A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.Journal of medical genetics · 2015Article
- Breast cancer risks and risk prediction models.Breast care (Basel, Switzerland) · 2015Review
- The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.Human molecular genetics · 2014Article
- BRCA-associated ovarian cancer: from molecular genetics to risk management.BioMed research international · 2014Review
- Role of DNA repair and cell cycle control genes in ovarian cancer susceptibility.Molecular biology reports · 2013Article
- Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families.British journal of cancer · 2012Article
- Germline mutations in RAD51D confer susceptibility to ovarian cancer.Nature genetics · 2011Article
- Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.International journal of cancer · 2011Article
- Breast cancer susceptibility variants alter risk in familial ovarian cancer.Familial cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To establish the contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer, we have analyzed both genes in DNA samples obtained from an affected individual in each of 112 families containing at least two cases of epithelial ovarian cancer. Germline mutations were found in 43% of the families; BRCA1 mutations were approximately four times more common than BRCA2 mutations. The extent of family history of ovarian and breast cancers was strongly predictive of BRCA1-mutation status. Segregation analysis suggests that a combination of chance clustering of sporadic cases and insensitivity of mutation detection may account for the remaining families; however, the contribution of other genes cannot be excluded. We discuss the implications for genetic testing and clinical management of familial ovarian cancer arising from the data presented in these studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.